Novavax, Inc. (NVAX)
Pre-market: 05:32AM EDT
| Previous close | 180.99 |
| Open | 180.51 |
| Bid | 196.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 179.67 - 195.61 |
| 52-week range | 70.00 - 331.68 |
| Volume | 4,627,542 |
| Avg. volume | 3,797,779 |
| Market cap | 14.402B |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.51 |
| Earnings date | 09 Aug 2021 - 13 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 258.00 |
- Motley Fool
Why Moderna Just Booked Another $3 Billion in Vaccine Orders and No One Cared
Any way you look at it, Moderna (NASDAQ: MRNA) is on a roll. Here's why Moderna just booked another $3 billion in vaccine orders and no one seemed to care. Moderna announced last week that the U.S. government was buying another 200 million doses of its COVID-19 vaccine.
- Yahoo Finance Video
Delta COVID-19 variant likely to become dominant U.S. strain: Doctor
Dr. Susannah Hills, Pediatric Airway surgeon and assistant professor of ENT at Columbia University Medical Center, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
- Motley Fool
Is Now the Time to Go All-In On Novavax Stock?
On June 14, Novavax (NASDAQ: NVAX) announced that its recombinant nanoparticle coronavirus vaccine, NVX-CoV2373, had demonstrated 93% overall efficacy against coronavirus variants in phase 3 trials -- and that number shot up to 100% for severe or critical COVID-19. The vaccine candidate was also well-tolerated, with serious adverse events spread out equally between placebo and treatment groups. Shares fell about 10% after Novavax published the results.
